In adults with Helicobacter pylori (H. pylori) infection, therapy based on Vonoprazan exhibited high efficacy and tolerability, according to a study published in "Annals of Pharmacotherapy". Ligang Liu et al. set out to investigate the pharmacology, effectiveness, safety, and possible function of Vonoprazan in combination with Amoxicillin or Amoxicillin plus Clarithromycin for the management of H. pylori infection.

Without any date limitations, the following search phrases were used in ClinicalTrials.gov, Cochrane Library, PubMed, and Embase: (Vonoprazan OR voquezna) AND ("H. pylori" OR "Helicobacter pylori" AND Amoxicillin. Based on various comparisons between the treatment regimens employed in each group, studies evaluating the effectiveness and safety of Vonoprazan with Amoxicillin and/or Clarithromycin were included and segregated into three groups.

There were 17 observational studies and 10 clinical trials. In patients who never had treatment before or who had infections resistant to Clarithromycin, Vonoprazan-based therapy showed stronger acid suppression and comparable to or higher effectiveness than proton pump inhibitor (PPI)-based therapy. Vonoprazan-based therapy is promising to combat H. pylori infection in adults.

With prolonged acid inhibition, a reduced risk of CYP2C19 polymorphism, and at least similar safety and effectiveness to PPI-based therapy in H. pylori-infected individuals, these regimens provide a valuable option. Hence, Vonoprazan-based therapy should be taken into consideration for some patients, such as those who have not responded to PPI-based therapies.